Adverse effects of drugs used to treat hematologic malignancies

Surveillance efforts from the research on adverse drug events and reports project

Charles L. Bennett*, Cara C. Tigue, Cara Angelotta, June M McKoy, Beatrice J. Edwards

*Corresponding author for this work

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Pharmaceuticals used to treat hematologic malignancies can lead to unexpected adverse events that involve a wide range of organ systems and physiological processes. The National Cancer Institute and National Heart Lung and Blood Institute-funded Research on Adverse Drug Events and Reports (RADAR) project - a collaboration of the Robert H. Lurie Comprehensive Cancer Center, the Department of Veterans Affairs, the Northwestern University Feinberg School of Medicine, and numerous academic institutions - identifies and evaluates unexpected adverse drug reactions associated with drugs used to treat malignant disorders. This article reviews the features of the safety program maintained by the U.S. Food and Drug Administration and the RADAR program.

Original languageEnglish (US)
Pages (from-to)365-372
Number of pages8
JournalSeminars in thrombosis and hemostasis
Volume33
Issue number4
DOIs
StatePublished - Jun 1 2007

Fingerprint

Hematologic Neoplasms
Drug-Related Side Effects and Adverse Reactions
Research
Pharmaceutical Preparations
Physiological Phenomena
National Heart, Lung, and Blood Institute (U.S.)
National Cancer Institute (U.S.)
Veterans
United States Food and Drug Administration
Medicine
Safety
Neoplasms

Keywords

  • Adverse drug reactions
  • Drug surveillance
  • Hematologic malignancies
  • Pharmaceutical safety

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{16225f449bb841b6bdac5db9dcfd4dbe,
title = "Adverse effects of drugs used to treat hematologic malignancies: Surveillance efforts from the research on adverse drug events and reports project",
abstract = "Pharmaceuticals used to treat hematologic malignancies can lead to unexpected adverse events that involve a wide range of organ systems and physiological processes. The National Cancer Institute and National Heart Lung and Blood Institute-funded Research on Adverse Drug Events and Reports (RADAR) project - a collaboration of the Robert H. Lurie Comprehensive Cancer Center, the Department of Veterans Affairs, the Northwestern University Feinberg School of Medicine, and numerous academic institutions - identifies and evaluates unexpected adverse drug reactions associated with drugs used to treat malignant disorders. This article reviews the features of the safety program maintained by the U.S. Food and Drug Administration and the RADAR program.",
keywords = "Adverse drug reactions, Drug surveillance, Hematologic malignancies, Pharmaceutical safety",
author = "Bennett, {Charles L.} and Tigue, {Cara C.} and Cara Angelotta and McKoy, {June M} and Edwards, {Beatrice J.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1055/s-2007-976172",
language = "English (US)",
volume = "33",
pages = "365--372",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "4",

}

Adverse effects of drugs used to treat hematologic malignancies : Surveillance efforts from the research on adverse drug events and reports project. / Bennett, Charles L.; Tigue, Cara C.; Angelotta, Cara; McKoy, June M; Edwards, Beatrice J.

In: Seminars in thrombosis and hemostasis, Vol. 33, No. 4, 01.06.2007, p. 365-372.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Adverse effects of drugs used to treat hematologic malignancies

T2 - Surveillance efforts from the research on adverse drug events and reports project

AU - Bennett, Charles L.

AU - Tigue, Cara C.

AU - Angelotta, Cara

AU - McKoy, June M

AU - Edwards, Beatrice J.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Pharmaceuticals used to treat hematologic malignancies can lead to unexpected adverse events that involve a wide range of organ systems and physiological processes. The National Cancer Institute and National Heart Lung and Blood Institute-funded Research on Adverse Drug Events and Reports (RADAR) project - a collaboration of the Robert H. Lurie Comprehensive Cancer Center, the Department of Veterans Affairs, the Northwestern University Feinberg School of Medicine, and numerous academic institutions - identifies and evaluates unexpected adverse drug reactions associated with drugs used to treat malignant disorders. This article reviews the features of the safety program maintained by the U.S. Food and Drug Administration and the RADAR program.

AB - Pharmaceuticals used to treat hematologic malignancies can lead to unexpected adverse events that involve a wide range of organ systems and physiological processes. The National Cancer Institute and National Heart Lung and Blood Institute-funded Research on Adverse Drug Events and Reports (RADAR) project - a collaboration of the Robert H. Lurie Comprehensive Cancer Center, the Department of Veterans Affairs, the Northwestern University Feinberg School of Medicine, and numerous academic institutions - identifies and evaluates unexpected adverse drug reactions associated with drugs used to treat malignant disorders. This article reviews the features of the safety program maintained by the U.S. Food and Drug Administration and the RADAR program.

KW - Adverse drug reactions

KW - Drug surveillance

KW - Hematologic malignancies

KW - Pharmaceutical safety

UR - http://www.scopus.com/inward/record.url?scp=34249931317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249931317&partnerID=8YFLogxK

U2 - 10.1055/s-2007-976172

DO - 10.1055/s-2007-976172

M3 - Review article

VL - 33

SP - 365

EP - 372

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 4

ER -